A randomized, double-blind comparison of atomoxetine and placebo on response inhibition and interference control in children and adolescents with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder symptoms

Jolanda M J van der Meer; Myriam Harfterkamp; Gigi van de Loo-Neus; Monika Althaus; Saskia W de Ruiter; A Rogier T Donders; Leo M J de Sonneville; Jan K Buitelaar; Pieter J Hoekstra; Nanda N J Rommelse

doi:10.1097/JCP.0b013e31829c764f

A randomized, double-blind comparison of atomoxetine and placebo on response inhibition and interference control in children and adolescents with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder symptoms

J Clin Psychopharmacol. 2013 Dec;33(6):824-7. doi: 10.1097/JCP.0b013e31829c764f.

Authors

Jolanda M J van der Meer¹, Myriam Harfterkamp, Gigi van de Loo-Neus, Monika Althaus, Saskia W de Ruiter, A Rogier T Donders, Leo M J de Sonneville, Jan K Buitelaar, Pieter J Hoekstra, Nanda N J Rommelse

Affiliation

¹ Department of Cognitive Neuroscience, Donders Institute for Brain Cognition and Behavior, Radboud University Nijmegen Medical Center and Karakter Child and Adolescent Psychiatry, University Center Nijmegen, Nijmegen, the Netherlands J.vanderMeer@psy.umcn.nl Department of Psychiatry University Medical Center Groningen University of Groningen Groningen, the Netherlands Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands Karakter Child and Adolescent Psychiatry, University Center Nijmegen, Nijmegen, the Netherlands Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands Karakter Child and Adolescent Psychiatry, University Center Nijmegen, Nijmegen, the Netherlands Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands Department of Clinical Child and Adolescent Studies, Leiden Institute for Brain and Cognition, Faculty of Social Sciences, University of Leiden, Leiden, the Netherlands Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen Medical Center and Karakter Child and Adolescent Psychiatry, University Center Nijmegen, Nijmegen, the Netherlands Karakter Child and Adolescent Psychiatry University Center Nijmegen and Department of Psychiatry Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands Karakter Child and Adolescent Psychiatry, University Center Nijmegen and Department of Psychiatry, Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands.

PMID: 24018545
DOI: 10.1097/JCP.0b013e31829c764f

No abstract available

Publication types

Comparative Study
Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adrenergic Uptake Inhibitors / therapeutic use*
Atomoxetine Hydrochloride
Attention Deficit Disorder with Hyperactivity / complications
Attention Deficit Disorder with Hyperactivity / drug therapy*
Attention Deficit Disorder with Hyperactivity / physiopathology
Child
Child Development Disorders, Pervasive / complications
Child Development Disorders, Pervasive / drug therapy*
Child Development Disorders, Pervasive / physiopathology
Double-Blind Method
Female
Humans
Male
Propylamines / therapeutic use*
Treatment Outcome

Substances

Adrenergic Uptake Inhibitors
Propylamines
Atomoxetine Hydrochloride

Associated data

ClinicalTrials.gov/NCT00380692